A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy
Latest Information Update: 21 Oct 2021
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe; Rosuvastatin; Simvastatin
- Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms ODYSSEY-Combo-II
- Sponsors Sanofi
- 17 Oct 2021 Results of Meta-Analysis from eight randomized, double-blind, placebo-controlled studies assessing Clinical Outcomes of PCSK9 Modulators in Patients with Established ASCVD published in the Pharmacotherapy
- 05 Sep 2018 Results of pooled data from 14 trials, were published in the Diabetic Medicine.
- 15 Nov 2017 Results of pooled analysis from ten ODYSSEY trials assessing characteristics of patients with less than 5% LDL-C reduction presented at the 90th Annual Scientific Sessions of the American Heart Association